Vincerx Pharma, Inc. (VINC)

0,8892 +0,0622 (+7,52%) Alla chiusura: 04:00PM EDT

Vincerx Pharma, Inc.

260 Sheridan Avenue
Suite 400
Palo Alto, CA 94306
United States
650 800 6676
https://vincerx.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 42

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Ahmed M. Hamdy M.D.	Co-Founder, Chairman & CEO	657,54k	N/D	1965
Dr. Raquel E. Izumi Ph.D.	Co-Founder, President, COO, Secretary & Director	591,54k	N/D	1970
Mr. Alexander A. Seelenberger M.B.A.	Chief Financial Officer	491,69k	N/D	1979
Mr. Tom C. Thomas J.D.	Founder, General Counsel & Chief Legal Officer	444,14k	N/D	1960
Dr. John C. Byrd M.D.	Founder & Chairman of Scientific Advisory Board	N/D	N/D	N/D
Dr. Hans-Georg Lerchen Ph.D.	Chief Scientific Officer	N/D	N/D	N/D
Ms. Gabriela Jairala	Sr Executive Director of Investor Relations & Corporate Communications	N/D	N/D	N/D
Ms. Karen Quarford	Vice President of Quality Operations & Compliance	N/D	N/D	N/D
Ms. Melissa Merrick SPHR	Senior Director of People & Culture and Head of Human Resource	N/D	N/D	N/D
Dr. Beatrix Stelte-Ludwig Ph.D.	Executive Chief Development Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Governance aziendale

L'ISS Governance QualityScore di Vincerx Pharma, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.